Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Company Shares of Rockwell Medical, Inc. Drops by -15.77% | Insider Trading Report - Insider Trading Report |
 |
 |
|
Rockwell Medical, Inc. (NASDAQ:RMTI) has lost 15.77% during the past week and dropped 6.18% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 13.87%. Rockwell Medical, Inc. (NASDAQ:RMTI) has underperformed the index by 5.2% in the last 4 weeks. Investors should watch out for further signals and trade with caution. For the current week, the company shares have a recommendation consensus of Buy. Rockwell Medical, Inc. is up 46.29% in the last 3-month period. Year-to-Date the stock performance stands at 47.57%. The company shares have rallied 48.29% in the past 52 Weeks. On July 17, 2015 The shares registered one year high of $18.9 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $15.57 and the 200 day moving average is recorded at $11.83. S&P 500 has rallied 5.09% during the last 52-weeks. Rockwell Medical, Inc. (NASDAQ:RMTI) witnessed a decline in the market cap on Friday as its shares dropped 5.13% or 0.82 points. After the session commenced at $15.9, the stock reached the higher end at $15.91 while it hit a low of $15.12. With the volume soaring to 1,315,256 shares, the last trade was called at $15.17. The company has a 52-week high of $18.8999. The company has a market cap of $761 million and there are 50,169,000 shares in outstanding. The 52-week low of the share price is $8.095. Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0% in the total insider ownership. Institutional Investors own 33.9% of Company shares. During last 3 month period, 24.11% of total institutional ownership has changed in the company shares. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. |
